Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Emergence of Resistance in Klebsiella aerogenes to Piperacillin-Tazobactam and Ceftriaxone.

Tytuł:
Emergence of Resistance in Klebsiella aerogenes to Piperacillin-Tazobactam and Ceftriaxone.
Autorzy:
Custodio MM; Department of Pharmacy, University of New Mexico Hospitals, Albuquerque, New Mexico, USA.
Sanchez D; University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA.
Anderson B; University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA.
Ryan KL; Department of Pharmacy, University of New Mexico Hospitals, Albuquerque, New Mexico, USA.
Walraven C; Department of Pharmacy, University of New Mexico Hospitals, Albuquerque, New Mexico, USA.
Mercier RC; University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA .
Źródło:
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2021 Jan 20; Vol. 65 (2). Date of Electronic Publication: 2021 Jan 20 (Print Publication: 2021).
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Washington, American Society for Microbiology
MeSH Terms:
Ceftriaxone*
Enterobacter aerogenes*
Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Microbial Sensitivity Tests ; Penicillanic Acid/pharmacology ; Piperacillin/pharmacology ; Piperacillin, Tazobactam Drug Combination/pharmacology ; beta-Lactamases
References:
Antimicrob Agents Chemother. 2000 Mar;44(3):561-7. (PMID: 10681318)
Antimicrob Agents Chemother. 2008 Mar;52(3):995-1000. (PMID: 18086837)
J Antimicrob Chemother. 2018 Jun 1;73(6):1530-1536. (PMID: 29566147)
Antimicrob Agents Chemother. 1997 Oct;41(10):2177-83. (PMID: 9333044)
Antimicrob Agents Chemother. 2007 Oct;51(10):3605-11. (PMID: 17646416)
Antimicrob Agents Chemother. 2012 Aug;56(8):4087-94. (PMID: 22585219)
Clin Microbiol Rev. 2009 Jan;22(1):161-82, Table of Contents. (PMID: 19136439)
Semin Respir Crit Care Med. 2006 Feb;27(1):34-44. (PMID: 16508880)
Antimicrob Agents Chemother. 2013 Dec;57(12):5811-9. (PMID: 24002098)
Clin Pharmacol Ther. 2014 Oct;96(4):438-48. (PMID: 24926779)
Crit Care Med. 2005 Apr;33(4):756-9. (PMID: 15818101)
Ann Intern Med. 1991 Oct 15;115(8):585-90. (PMID: 1892329)
Clin Infect Dis. 2014 Jun;58(11):1554-63. (PMID: 24647022)
Int J Antimicrob Agents. 2013 Mar;41(3):236-49. (PMID: 23313399)
Antimicrob Agents Chemother. 2001 Sep;45(9):2628-30. (PMID: 11502540)
J Antimicrob Chemother. 2012 Dec;67(12):2793-803. (PMID: 22915465)
Crit Care Med. 2003 Aug;31(8):2102-6. (PMID: 12973166)
Clin Infect Dis. 2015 May 1;60(9):1319-25. (PMID: 25586681)
Antimicrob Agents Chemother. 2015 Dec;59(12):7753-61. (PMID: 26438498)
Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):705-714. (PMID: 28486001)
Scand J Infect Dis. 2014 Nov;46(11):803-8. (PMID: 25262922)
Scand J Infect Dis Suppl. 1990;74:63-70. (PMID: 2097720)
JAMA. 2018 Sep 11;320(10):984-994. (PMID: 30208454)
Antimicrob Agents Chemother. 2012 Apr;56(4):2173-7. (PMID: 22290982)
Clin Microbiol Rev. 1995 Oct;8(4):557-84. (PMID: 8665470)
J Chemother. 1997 May;9 Suppl 3:29-37. (PMID: 9248978)
Clin Infect Dis. 2019 Sep 27;69(8):1446-1455. (PMID: 30838380)
Clin Infect Dis. 2013 Sep;57(6):781-8. (PMID: 23759352)
J Clin Microbiol. 2005 Dec;43(12):5945-9. (PMID: 16333080)
Am J Respir Crit Care Med. 1998 Jan;157(1):76-80. (PMID: 9445281)
J Antimicrob Chemother. 2016 Feb;71(2):296-306. (PMID: 26542304)
Crit Care Med. 2008 May;36(5):1500-6. (PMID: 18434883)
Antimicrob Agents Chemother. 2017 May 24;61(6):. (PMID: 28320724)
Contributed Indexing:
Keywords: AmpC; AmpC derepression; Klebsiella aerogenes; ceftriaxone; piperacillin-tazobactam
Substance Nomenclature:
0 (Anti-Bacterial Agents)
157044-21-8 (Piperacillin, Tazobactam Drug Combination)
75J73V1629 (Ceftriaxone)
87-53-6 (Penicillanic Acid)
EC 3.5.2.6 (beta-Lactamases)
X00B0D5O0E (Piperacillin)
Entry Date(s):
Date Created: 20201103 Date Completed: 20210617 Latest Revision: 20240330
Update Code:
20240330
PubMed Central ID:
PMC7848979
DOI:
10.1128/AAC.01038-20
PMID:
33139285
Czasopismo naukowe
We examined the effects of piperacillin-tazobactam (TZP) concentration and bacterial inoculum on in vitro killing and the emergence of resistance in Klebsiella aerogenes The MICs for 15 clinical respiratory isolates were determined by broth microdilution for TZP and by Etest for ceftriaxone (CRO) and cefepime (FEP). The presence of resistance in TZP-susceptible isolates ( n  = 10) was determined by serial passes over increasing concentrations of TZP-containing and CRO-containing agar plates. Isolates with growth on TZP 16/4-μg/ml and CRO 8-μg/ml plates ( n  = 5) were tested in high-inoculum (HI; 7.0 log 10 CFU/ml) and low-inoculum (LI; 5.0 log 10 CFU/ml) time-kill studies. Antibiotic concentrations were selected to approximate TZP 3.375 g every 8 h (q8h) via a 4-h prolonged-infusion free peak concentration (40 μg/ml [TZP40]), peak epithelial lining fluid (ELF) concentrations, and average AUC 0-24 values for TZP (20 μg/ml [TZP20] and 10 μg/ml [TZP10], respectively), the ELF FEP concentration (14 μg/ml), and the average AUC 0-24 CRO concentration (6 μg/ml). For HI, FEP exposure significantly reduced 24-h inocula against all comparators ( P  ≤ 0.05) with a reduction of 4.93 ± 0.64 log 10 CFU/ml. Exposure to TZP40, TZP20, and TZP10 reduced inocula by 0.81 ± 0.43, 0.21 ± 0.18, and 0.05 ± 0.16 log 10 CFU/ml, respectively. CRO-exposed isolates demonstrated an increase of 0.42 ± 0.39 log 10 CFU/ml compared to the starting inocula, with four of five CRO-exposed isolates demonstrating TZP-nonsusceptibility. At LI after 24 h of exposure to TZP20 and TZP10, the starting inoculum decreased by averages of 2.24 ± 1.98 and 2.91 ± 0.50 log 10 CFU/ml, respectively. TZP demonstrated significant inoculum-dependent killing, warranting dose optimization studies.
(Copyright © 2021 American Society for Microbiology.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies